The role of topical 5% acyclovir and 1% hydrocortisone cream (xerese™) in the treatment of recurrent herpes simplex labialis

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 1-6

  Hull, Christopher M ^a   Brunton, Stephen ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acyclovir; Antiviral; Cold sores; Corticosteroids; Herpes simplex labialis; Herpes simplex virus; Hydrocortisone

Indexed keywords

ACICLOVIR; ACICLOVIR PLUS HYDROCORTISONE; ANTIVIRUS AGENT; CORTICOSTEROID DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; XERESE; ANTIINFLAMMATORY AGENT; HYDROCORTISONE;

APPLICATION SITE DRYNESS; APPLICATION SITE INFLAMMATION; APPLICATION SITE IRRITATION; ARTICLE; ASTHMA; CHAPPED LIPS; CREAM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY LIP; ERYTHEMA; HEALING; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HUMAN; LIP DISEASE; PHOTOTOXICITY; RECURRENT DISEASE; RHINITIS; RHINOPHARYNGITIS; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; DRUG COMBINATION; IMMUNOCOMPETENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TOPICAL DRUG ADMINISTRATION; VIROLOGY;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; DRUG COMBINATIONS; HERPES LABIALIS; HUMANS; HYDROCORTISONE; IMMUNOCOMPETENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 78049525928     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2216     Document Type: Article

References (27)

1. Prevention and control of herpesvirus diseases. Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO meeting. Bull World Health Organ. 1985;63(2):185-201.
2. World Health Organization. Prevention and control of herpesvirus diseases. Part 2. Epidemiology and immunology. Bull World Health Organ. 1985;63(3):427-444.
3. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2seroprevalence in the United States. JAMA. 2006;296(8):964-973.
4. Malvy D, Ezzedine K, Lancon F, et al. Epidemiology of orofacial herpes simplex virus infections in the general population in France: results of the HERPIMAX study. J Eur Acad Dermatol Venereol. 2007;21(10):1398-1403.
5. Löwhagen GB, Tunbäck P, Bergström T. Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates. Acta Derm Venereol. 2002;82(2):118-120.
6. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57(5):737-763.
7. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes. 2002;9(3):64-69.
8. Nikkels AF, Pièrard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol. 2002;3(7):475-487.
9. Hull C, Spruance S. Situational antiviral drug prophylaxis for HSV type 1 recurrences. Herpes. 2007;14(2):37-40.
10. Strand A, Böttiger D, Wheeler W. Combination 5% acyclovir and 1% hydrocortisone cream (Xerese™) is safe in adolescents with recurrent herpes simplex labialis [abstract]. Paper presented at: Annual Meeting of the American Osteopathic Association (AOA); October 24-28, 2010; San Francisco, CA.
11. Hull C. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. In press.
12. Xerese [package insert]. Huddinge, Sweden: Medivir AB; 2009.
13. Spruance SL. Herpes simplex labialis. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, eds. Clinical Management of Herpes Viruses. Amsterdam, The Netherlands: IOS Press; 1995:3-42.
14. Jensen LA, Hoehns JD, Squires CL. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann Pharmacother. 2004;38(4):705-709.
15. Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs. 2006;66(18):2397-2416.
16. Spruance SL. Treatment of herpes simplex labialis. In: De Clerq E, ed. Clinical Use of Antiviral Drugs. Boston, MA: Martinus Nijhoff; 1988:67-86.
17. Raborn GW, McGaw WT, Grace M, Percy J, Samuels S. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial. Oral Surg Oral Med Oral Pathol. 1989;67(6):676-679.
18. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46(7):2238-2243.
19. Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest. 1989;83(2):490-496.
20. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest. 1985;75(1):226-233.
21. Spruance SL, Evans TG, McKeough MB, et al. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 1995;28(1):39-55.
22. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother. 2002;46(6):1870-1874.
23. Hull C, McKeough M, Sebastian K, Kriesel J, Spruance S. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009;23(3):263-267.
24. Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J Infect Dis. 2000;181(6):1906-1910.
25. Brytting M, Arlander E, Gever L, Wheeler W. Recurrent herpes labialis is not associated with acyclovir resistance following the topical application of acyclovir 5% and hydrocortisone 1% cream. Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
26. Wheeler W, Gever L, Arlander E, et al. Phototoxicity is not observed following the topical application of acyclovir 5% and hydrocortisone 1% cream [abstract]. Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA.
27. Gever L, Wheeler W. Topical application of 5% acyclovir and 1% hydrocortisone cream (Xerese™) does not cause phototoxicity in healthy volunteers [abstract]. Paper presented at: Annual Meeting of the American Osteopathic Association (AOA); October 24-28, 2010; San Francisco, CA.